Sangamo Therapeutics (SGMOQ) Other Non Operating Income (2024 - 2025)
Sangamo Therapeutics (SGMOQ) posted Other Non Operating Income of -$21000.0 for Q4 2025, down 119.63% on a QoQ basis from $107000.0 in Q3 2025, and down 101.12% year-over-year from $1.9 million in Q4 2024.
Powered by 
Analysis
Sangamo Therapeutics (SGMOQ) Other Non Operating Income (2024 - 2025) Analysis & Trends
Sangamo Therapeutics has reported Other Non Operating Income for 2 years, with the latest figure at -$21000.0 in Q4 2025.
- On a quarterly basis, Other Non Operating Income fell 101.12% year-over-year to -$21000.0 in Q4 2025; TTM through Dec 2025 was -$3.6 million, a 181.95% decrease from a year earlier, with the FY2025 full-year figure at -$3.6 million, down 181.95% from the prior year.
- Other Non Operating Income was -$21000.0 for Q4 2025 at Sangamo Therapeutics, down from $107000.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $2.1 million in Q1 2024, with the low at -$2.5 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.20 Bn | 9.36 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.20 Bn | 5.20 Bn | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.50 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.72 Bn | 251.50 Mn |
| 5 | uniQure | 3.07 Bn | 3.07 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.67 Bn | 2.67 Bn | - |
| 7 | Precigen | 2.43 Bn | 2.43 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.54 Bn | 251.87 Mn |
| 9 | Vericel | 2.00 Bn | 1.84 Bn | 56.40 Mn |
| 10 | Sangamo Therapeutics | 43.15 Mn | 22.20 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -21,000.00 |
| Sep 30, 2025 | 107,000.00 |
| Jun 30, 2025 | -2.49 Mn |
| Mar 31, 2025 | -1.16 Mn |
| Dec 31, 2024 | 1.87 Mn |
| Sep 30, 2024 | -221,000.00 |
| Jun 30, 2024 | 614,000.00 |
| Mar 31, 2024 | 2.08 Mn |